GGrantIndex
Sort

51,593 grants matching hepatitis

INVESTIGATION OF ERBB SIGNALING IN COLORECTAL CANCER DURING LIVER METASTASIS

$408,312
David W. Threadgill · Univ Of North Carolina Chapel Hill · P50 · FY2008 · CA

Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism

$408,310
Robert E Fleming · Saint Louis University · R01 · FY2015 · DK

Cyclin D1/CDK4 Complex in Hepatocyte Proliferation

$408,309
Jeffrey H Albrecht · Hennepin Healthcare Research Institute · R01 · FY2014 · DK

Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

$408,299
Mehmet Sofuoglu · Yale University · R01 · FY2013 · DA

Novel Pathogen Recognition Pathways and Control of Hepatitis A Virus

$408,288
Stanley M Lemon · Univ Of North Carolina Chapel Hill · U19 · FY2018 · AI

Role of chitinase-3-like-1 (Chi3l1) in acetaminophen-induced liver injury

$408,270
Cynthia Ju · University Of Texas Hlth Sci Ctr Houston · R01 · FY2019 · DK

FUNCTION OF THE HEMOCHROMATOSIS PROTEIN

$408,232
Caroline Enns · Oregon Health & Science University · R01 · FY2009 · DK

Role of NgBR in Hepatic Steatosis

$408,222
Qing Miao · Nyu Long Island School Of Medicine · R01 · FY2021 · DK

Myeloid FoxO1 in Lipid Metabolism

$408,222
Hengjiang Henry Dong · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · DK

Novel Pathogen Recognition Pathways and Control of Hepatitis A Virus

$408,220
Stanley M Lemon · Univ Of North Carolina Chapel Hill · U19 · FY2015 · AI

Role of Uhrf1 in Liver Development, Regeneration and Carciogenesis

$408,198
Chinweike Ukomadu · Brigham And Women'S Hospital · R01 · FY2010 · DK

HUMAN LIVER CYTOCHROMES P450

$408,155
California Toxicology Research Institute · R01 · FY2002 · GM

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV

$408,139
Robert A Schnoll · University Of Pennsylvania · R01 · FY2020 · CA

Core D: Clinical Sciences

$408,139
Jeffrey M Jacobson · Case Western Reserve University · P30 · FY2023 · AI

AAV vectors for prevention and therapy of HCV infection

$408,128
Research Inst Nationwide Children'S Hosp · R01 · FY2005 · AI

Models for Optimal Liver Transplant Outcomes

$408,122
Mayo Clinic · R01 · FY2005 · DK

Models for Optimal Liver Transplant Outcomes

$408,122
Mayo Clinic · R01 · FY2004 · DK

Mechanisms of insulin secretion mediated by alpha cells

$408,119
Jonathan E Campbell · Duke University · R01 · FY2023 · DK

HCV Disease Management in HIV- HCV Coinfected IDUs

$408,118
Mark Sebastian Sulkowski · Johns Hopkins University · R01 · FY2012 · DA

Role of Intestinal Microbiota in Dyslipidemia and Atherosclerosis Induced by Ambient Ultrafine Particles

$408,073
Jesus Antonio Araujo · University Of California Los Angeles · R01 · FY2018 · ES

Correlates of protective immunity to HCV and rational vaccine design: Admin Core

$408,062
Arash Grakoui · Emory University · U19 · FY2022 · AI

Correlates of protective immunity to HCV and rational vaccine design: Project 1

$408,062
Naglaa H. Shoukry · Emory University · U19 · FY2022 · AI

Correlates of protective immunity to HCV and rational vaccine design: Clinical Core

$408,062
Naglaa H. Shoukry · Emory University · U19 · FY2022 · AI

Correlates of protective immunity to HCV and rational vaccine design: Project 2

$408,061
Arash Grakoui · Emory University · U19 · FY2022 · AI

Correlates of protective immunity to HCV and rational vaccine design: Project 3

$408,060
Rama Rao Amara · Emory University · U19 · FY2022 · AI